SCHEMBL2809677

SCHEMBL2809677

CN(C)c1ncc2c(n1)CNC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 6/20 0.36
CYP1A2 P05177 6/20 0.36
CASP1 P29466 5/20 0.36
CASP7 P55210 5/20 0.36
ALDH1A1 P00352 4/20 0.36
HPGD P15428 3/20 0.36
CYP2D6 P10635 1/20 0.36
CLK4 Q9HAZ1 2/20 0.35
HTR2C P28335 2/20 0.34
HSP90AA1 P07900 1/20 0.33
KDM4E B2RXH2 1/20 0.32
ALOX15 P16050 1/20 0.32
POLB P06746 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MAPK1 P28482 2/20 0.31
MEN1 O00255 1/20 0.31
CYP3A4 P08684 1/20 0.31
TSHR P16473 1/20 0.31
KMT2A Q03164 1/20 0.31
BRD9 Q9H8M2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28410160 0.98 HSD17B10 (0.35) HSD17B10CYP1A2CASP1CASP7ALDH1A1
SCHEMBL785776 0.84 POLB (0.48) HPGDHTR2CHSP90AA1POLBSMN1; SMN2
SCHEMBL18819035 0.82 DYRK1A (0.35) HTR2C
Hydrochloric Acid SCHEMBL28413259 0.80 DYRK1A (0.34) HTR2C
SCHEMBL18536681 0.76 GBA1 (0.36) HTR2C
SCHEMBL1622227 0.75 HTR2C (0.48) HSD17B10CYP1A2CASP1CASP7ALDH1A1
SCHEMBL1528492 0.75 HTR2C (0.37) HTR2CHSP90AA1POLBSMN1; SMN2
Hydrochloric Acid SCHEMBL1622905 0.74 HTR2C (0.47) HTR2CHSP90AA1POLBSMN1; SMN2
Hydrochloric Acid SCHEMBL2874635 0.73 HTR2C (0.36) HTR2CHSP90AA1POLBSMN1; SMN2
SCHEMBL17149783 0.72 CDK5 (0.44) HSD17B10CYP1A2CASP1CASP7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017071636-A1 PHTHALAZINE KETONE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2017-05-04 WO disclosed
US-20100240638-A1 Organic Compounds and their uses NOVARTIS AG (CH) 2010-09-23 US disclosed
EP-2125757-A1 MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS Novartis AG (CH) 2009-12-02 EP disclosed
WO-2008101665-A1 MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS NOVARTIS AG (CH) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240638-A1 Organic Compounds and their uses OAT, HAVCR2, CYP3A43 HSD17B10 310/4885CYP1A2 36/4885CASP1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.